Division of Cardiology, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Cardiac Conditions in Oncology Program, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Division of Cardiology, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68. doi: 10.1016/j.jacc.2014.01.073. Epub 2014 Apr 2.
The literature exploring the utility of advanced echocardiographic techniques (such as deformation imaging) in the diagnosis and prognostication of patients receiving potentially cardiotoxic cancer therapy has involved relatively small trials in the research setting. In this systematic review of the current literature, we describe echocardiographic myocardial deformation parameters in 1,504 patients during or after cancer chemotherapy for 3 clinically-relevant scenarios. The systematic review was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines using the EMBASE (1974 to November 2013) and MEDLINE (1946 to November 2013) databases. All studies of early myocardial changes with chemotherapy demonstrate that alterations of myocardial deformation precede significant change in left ventricular ejection fraction (LVEF). Using tissue Doppler-based strain imaging, peak systolic longitudinal strain rate has most consistently detected early myocardial changes during therapy, whereas with speckle tracking echocardiography (STE), peak systolic global longitudinal strain (GLS) appears to be the best measure. A 10% to 15% early reduction in GLS by STE during therapy appears to be the most useful parameter for the prediction of cardiotoxicity, defined as a drop in LVEF or heart failure. In late survivors of cancer, measures of global radial and circumferential strain are consistently abnormal, even in the context of normal LVEF, but their clinical value in predicting subsequent ventricular dysfunction or heart failure has not been explored. Thus, this systematic review confirms the value of echocardiographic myocardial deformation parameters for the early detection of myocardial changes and prediction of cardiotoxicity in patients receiving cancer therapy.
探讨在接受潜在心脏毒性癌症治疗的患者中应用先进超声心动图技术(如应变成像)的实用性的文献,主要涉及研究环境中的相对较小规模的试验。在对当前文献的系统评价中,我们描述了在癌症化疗期间或之后的 1504 例患者的超声心动图心肌应变参数,涉及 3 种临床相关情况。系统评价是按照 PRISMA(系统评价和荟萃分析的首选报告项目)指南进行的,使用了 EMBASE(1974 年至 2013 年 11 月)和 MEDLINE(1946 年至 2013 年 11 月)数据库。所有关于化疗早期心肌变化的研究均表明,心肌应变的改变先于左心室射血分数(LVEF)的显著变化。使用组织多普勒应变成像,收缩期纵向应变率峰值最一致地检测到治疗期间的早期心肌变化,而对于斑点追踪超声心动图(STE),收缩期整体纵向应变(GLS)峰值似乎是最佳测量指标。STE 治疗期间 GLS 的早期减少 10%-15%似乎是预测心脏毒性的最有用参数,定义为 LVEF 或心力衰竭下降。在癌症的晚期幸存者中,即使在 LVEF 正常的情况下,整体径向和圆周应变的测量值也持续异常,但它们在预测随后的心室功能障碍或心力衰竭方面的临床价值尚未得到探讨。因此,本系统评价证实了超声心动图心肌应变参数在检测接受癌症治疗的患者心肌变化和预测心脏毒性方面的价值。